Clinical Trial

Cardiac Amyloidosis in Patients With Aortic Stenosis

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS), compare the clinical characteristics between patients with isolated AS and those with AS complicated by CA (CA-AS), and simultaneously explore the impact of transcatheter aortic valve replacement (TAVR) on serum transthyretin (TTR) levels in patients with AS complicated by transthyretin amyloidosis (ATTR-AS), as well as its influence on the treatment outcomes of patients with isolated AS and ATTR-AS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-05.
Trial Details
NCT Number NCT07170306
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Aortic Stenosis, Transthyretin Amyloid Cardiomyopathy
Enrollment 143 participants
Start Date 2026-01-31
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-20